Business & Economics
Hepatitis C
100%
Cost-utility
79%
Genotype
70%
Therapy
45%
Quality-adjusted Life Years
17%
Virus
16%
Cost Savings
5%
Willingness-to-pay
5%
Cost-utility Analysis
4%
Liver
4%
Cost-effectiveness
4%
Health Costs
4%
Tailoring
3%
Transition Probability
3%
Infection
3%
Costs
3%
Cohort
3%
Simulation Model
3%
Costs and Benefits
2%
Scenarios
2%
Medicine & Life Sciences
Chronic Hepatitis C
60%
Genotype
41%
Costs and Cost Analysis
35%
Duration of Therapy
15%
Quality-Adjusted Life Years
14%
Fibrosis
12%
Hepacivirus
12%
Therapeutics
9%
Economic Models
4%
Guidelines
4%
Insurance Benefits
3%
Standard of Care
3%
Liver Cirrhosis
3%
Health Care Costs
3%
Virus Diseases
2%
RNA
2%
Social Sciences
contagious disease
56%
costs
32%
utility analysis
5%
willingness to pay
4%
simulation model
4%
economic model
4%
scenario
2%
health
1%
evidence
1%